EP1186303A3 - Ein Neutrophilhemmender Faktor und ein selektive NMDA-NR2B Rezeptor Antagonisten enthaltende Kombinationspräparate zur Behandlung von Schlaganfällen und traumatischen Gehirnschäden - Google Patents

Ein Neutrophilhemmender Faktor und ein selektive NMDA-NR2B Rezeptor Antagonisten enthaltende Kombinationspräparate zur Behandlung von Schlaganfällen und traumatischen Gehirnschäden Download PDF

Info

Publication number
EP1186303A3
EP1186303A3 EP01307246A EP01307246A EP1186303A3 EP 1186303 A3 EP1186303 A3 EP 1186303A3 EP 01307246 A EP01307246 A EP 01307246A EP 01307246 A EP01307246 A EP 01307246A EP 1186303 A3 EP1186303 A3 EP 1186303A3
Authority
EP
European Patent Office
Prior art keywords
antagonist
treatment
brain injury
receptor antagonist
traumatic brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01307246A
Other languages
English (en)
French (fr)
Other versions
EP1186303A2 (de
Inventor
Bertrand Leo Pfizer Global Chenard
Frank Samuel Pfizer Global Menniti
Mario Davis Pfizer Global Saltarelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of EP1186303A2 publication Critical patent/EP1186303A2/de
Publication of EP1186303A3 publication Critical patent/EP1186303A3/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01307246A 2000-09-06 2001-08-24 Ein Neutrophilhemmender Faktor und ein selektive NMDA-NR2B Rezeptor Antagonisten enthaltende Kombinationspräparate zur Behandlung von Schlaganfällen und traumatischen Gehirnschäden Withdrawn EP1186303A3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23094400P 2000-09-06 2000-09-06
US230944P 2000-09-06

Publications (2)

Publication Number Publication Date
EP1186303A2 EP1186303A2 (de) 2002-03-13
EP1186303A3 true EP1186303A3 (de) 2003-12-10

Family

ID=22867173

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01307246A Withdrawn EP1186303A3 (de) 2000-09-06 2001-08-24 Ein Neutrophilhemmender Faktor und ein selektive NMDA-NR2B Rezeptor Antagonisten enthaltende Kombinationspräparate zur Behandlung von Schlaganfällen und traumatischen Gehirnschäden

Country Status (6)

Country Link
US (1) US6667317B2 (de)
EP (1) EP1186303A3 (de)
JP (1) JP2002322095A (de)
BR (1) BR0103888A (de)
CA (1) CA2356557A1 (de)
MX (1) MXPA01008994A (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
UA79248C2 (en) * 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
EP1598065A2 (de) * 2002-07-12 2005-11-23 Japan Science and Technology Agency Arzneimittel zur Verbesserung der Prognose einer Gehirnverletzung
US9254279B2 (en) * 2004-05-12 2016-02-09 Baxter International Inc. Nitric oxide scavengers
HU227000B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
US8101600B2 (en) * 2008-12-23 2012-01-24 Brookhaven Science Associates, Llc Method of treating depression
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP2542254B1 (de) 2010-02-11 2018-09-26 Northwestern University Nmda-rezeptor-agonisten und ihre verwendungen
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN103230581B (zh) * 2011-11-10 2016-12-21 陈锦辉 用于治疗创伤性脑损伤的组合物和方法
BR112015018095A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor nmda de espiro-lactama e usos dos mesmos
KR102410989B1 (ko) 2013-01-29 2022-06-17 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
WO2014120800A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
ES2935352T3 (es) 2013-01-29 2023-03-06 Aptinyx Inc Moduladores de receptores NMDA de espiro-lactama y sus usos
US9120750B2 (en) 2013-03-07 2015-09-01 Northwestern University 2-Aminopyridine-based selective neuronal nitric oxide synthase inhibitors
US9951014B2 (en) 2014-11-04 2018-04-24 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
US10759791B2 (en) 2014-11-04 2020-09-01 Northwestern University Mammalian and bacterial nitric oxide synthase inhibitors
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201283A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112019001768A2 (pt) 2016-08-01 2019-06-11 Aptinyx Inc moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
AU2017306164B2 (en) 2016-08-01 2021-10-21 Aptinyx Inc. Spiro-lactam NMDA modulators and methods of using same
ES2973283T3 (es) 2016-08-01 2024-06-19 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de receptores de NMDA espirolactámicos y usos de los mismos
CN110996948A (zh) 2017-06-12 2020-04-10 格莱泰施有限责任公司 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2023133230A1 (en) * 2022-01-08 2023-07-13 Sohn Joanna Monoacetyldiglycerides (plag) as a mitigating agent for traumatic brain injury and ischemia-reperfusion injury

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919900A (en) * 1992-05-11 1999-07-06 Corvas International, Inc. Modified hookworm neutrophil inhibitors
WO1999044640A1 (en) * 1998-03-06 1999-09-10 Merck Sharp & Dohme Limited Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor
US6046213A (en) * 1994-08-18 2000-04-04 Pfizer Inc. Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
ATE207498T1 (de) * 1992-05-11 2001-11-15 Corvas Int Inc Neutrophilen inhibitoren aus nematoden
JPH11505828A (ja) * 1995-05-26 1999-05-25 ファイザー・インコーポレーテッド パーキンソン症候群の治療用の選択的ｎｍｄａアンタゴニスト含有組合せ
DK0843661T3 (da) * 1995-08-11 2002-07-22 Pfizer (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
GB9804885D0 (en) * 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919900A (en) * 1992-05-11 1999-07-06 Corvas International, Inc. Modified hookworm neutrophil inhibitors
US6046213A (en) * 1994-08-18 2000-04-04 Pfizer Inc. Neuroprotective 3-(piperidinyl-1)-chroman-4,7-diol and 1-(4-hydroxyphenyl)-2-(piperidinyl-1)-alkanol derivatives
WO1999044640A1 (en) * 1998-03-06 1999-09-10 Merck Sharp & Dohme Limited Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
T.STEINER, W.HACKE: "Combination therapy with neuroprotectants and thrombolytics in acute ischaemic stroke", EUROPEAN NEUROLOGY, vol. 40, no. 1, 1998, pages 1 - 8, XP001064183 *

Also Published As

Publication number Publication date
MXPA01008994A (es) 2004-11-10
CA2356557A1 (en) 2002-03-06
US20020045656A1 (en) 2002-04-18
US6667317B2 (en) 2003-12-23
JP2002322095A (ja) 2002-11-08
EP1186303A2 (de) 2002-03-13
BR0103888A (pt) 2002-06-04

Similar Documents

Publication Publication Date Title
EP1186303A3 (de) Ein Neutrophilhemmender Faktor und ein selektive NMDA-NR2B Rezeptor Antagonisten enthaltende Kombinationspräparate zur Behandlung von Schlaganfällen und traumatischen Gehirnschäden
TWI255719B (en) Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
NZ601544A (en) Combination therapy for the treatment of ocular neovascular disorders
HUP0401192A3 (en) Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds
IL139862A0 (en) Thiazolidine or pyrrolidine derivatives as dipeptidyl peptidase iv effectors and pharmaceutical compositions containing the same
WO2004093814A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a sodium channel blocker
EP1202725A4 (de) Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen
WO2001041753A3 (en) Therapeutic compositions and methods for treating periodontitis with antiinflamatory compounds
EP1348466A3 (de) Schmerzbehandlung mit Adenosin-Tetraphosphaten
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
WO2005082070A3 (en) Compositions and methods for the systemic treatment of arthritis
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
PL1796725T3 (pl) Leczenie lub profilaktyka krwawień nieplanowych u kobiet przyjmujących lek zawierający progestogen
EP1108426A3 (de) Anwendung von Prostaglandinagonisten zur Behandlung der Erektionstörungen und Impotenz
WO2005023189A3 (en) Method of cox-2 selective inhibitor and nitric oxide-donating agent
GR20020100478A (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
YU57803A (sh) Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja
EP1284141A3 (de) Pharmazeutische Kombinationspräparate zur Behandlung neurodegenerativer Erkrankungen, enthaltend Inhibitoren der neuronalen Stickoxid-Synthase
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
EP0870502A3 (de) Verwendung von Adenosinaufnahmeinhibitoren zur Herstellung eines Arzneimittels zur Behandlung von Pankreatitis
WO2004093813A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
SE9902597D0 (sv) New use
MY122477A (en) Sertraline oral concentrate
AP2004003053A0 (en) Pharmaceutical combinations of adenosine A-2A and beta-2-adrenergic receptor agonists
WO2001044270A3 (en) Methods for treating and preventing diabetic complications by use of angiotensin-related peptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010908

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20071026

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080301